AdvancePCS Uses Medco Strategy To Win Favor On Wall Street
The Advance Paradigm/PCS merger is playing well on Wall Street as investors respond favorably to the PBM's argument that its increased bulk will increase its clout with manufacturers.
You may also be interested in...
Acambis foresees profit margins in the range of 30% to 40% from its contract with the Department of Health & Human Services to stockpile 155 mil. doses of smallpox vaccine
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011